Edwin Roman, DPM
Foot & Ankle Surgery · Williston, NYNPI 1407871700
Payments from drug & device makers
Across 53 payments — averaging $112.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Paragon 28, Inc.$4K
- Smith+Nephew$1K
- Paratek Pharmaceuticals, Inc.$284
- Kerecis Limited$132
- DJO, LLC$128
- Kowa Pharmaceuticals America, Inc.$116
- plus $353 from 7 others
What the payments were for
- Travel & lodging$3,93866%
- Food & beverage$1,91932%
- Education$1282%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Paragon 28, Inc. | 8 | $3,587 |
| Smith+Nephew | 14 | $1,385 |
| Paratek Pharmaceuticals, Inc. | 11 | $284 |
| Kerecis Limited | 3 | $132 |
| DJO, LLC | 2 | $128 |
| Kowa Pharmaceuticals America, Inc. | 2 | $116 |
| Amgen(2 entities) | 2 | $106 |
| Sandoz | 3 | $69 |
| Stryker | 2 | $63 |
| Treace Medical Concepts, Inc. | 3 | $59 |
| Aroa Biosurgery Incorporated | 1 | $22 |
| Integra Lifesciences Corporation | 1 | $17 |
| Hartmann USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Lapidus Nail$1,187
- Product Portfolio$1,128
- Oasis$993
- VERSAJET II$877
- Renasys$752
- Grafix$752
- PICO$752
- Stravix$241
- NUZYRA$112
- DR COMFORT$108
- Seglentis$102
How this compares
$5,984 in reported general payments places this provider in the 75th percentile of 652 foot & ankle surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JubliaEfinaconazole | 31 | $38,896 |
| Ammonium Lactate | 217 | $6,953 |
| Ciclopirox | 115 | $5,240 |
| Lidocaine | 58 | $3,778 |
| Diclofenac Sodium | 154 | $3,749 |
| Clobetasol Propionate | 29 | $1,830 |
| CiclopiroxCiclopirox Olamine | 72 | $1,624 |
| Mupirocin | 69 | $832 |
| Ketoconazole | 21 | $686 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 21 | $485 |
| Mometasone Furoate | 30 | $482 |
| Duloxetine Hcl | 33 | $359 |
| Methocarbamol | 19 | $342 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 14 | $338 |
| Triamcinolone Acetonide | 50 | $288 |
Paid to pharmacies, not to this prescriber.
Other foot & ankle surgery in Williston
- James McWilliamHarrison$4.7M
- Jonathan DelandNew York$4.1M
- George Vitole Roy$2.5M
- Constantine DemetracopoulosNew York$888K
- Anne JohnsonNew York$815K
- Scott EllisNew York$644K
- John KennedyNew York$613K
- Michael KellerKingston$532K
- Judith BaumhauerRochester$365K
- Edward AzarBrooklyn$224K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.